{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:42:55Z","timestamp":1793090575426,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006364","name":"French National Cancer Institute","doi-asserted-by":"publisher","award":["PHRC \\u2212K 2015\\u2013117"],"award-info":[{"award-number":["PHRC \\u2212K 2015\\u2013117"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.radonc.2025.111326","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T16:47:43Z","timestamp":1765298863000},"page":"111326","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Adjuvant radiotherapy in patients with pathological high-risk bladder cancer: Acute toxicity results from a randomized multicentre phase II trial (Bladder-ART\/GETUG-AFU30)"],"prefix":"10.1016","volume":"214","author":[{"given":"Paul","family":"Sargos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9raldine","family":"Pignot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7926-4671","authenticated-orcid":false,"given":"Carine","family":"Bellera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Pommier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2918-3117","authenticated-orcid":false,"given":"Etienne","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Clavere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Hennequin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Hoepffner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1806-1448","authenticated-orcid":false,"given":"Gautier","family":"Marcq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Roumigui\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Crouzet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Cormier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4957-6192","authenticated-orcid":false,"given":"Vanessa","family":"Schartner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mie","family":"Huchet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6019-7309","authenticated-orcid":false,"given":"David","family":"Pasquier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Khalifa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2025.111326_b0005","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European Association of Urology guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 guidelines","volume":"85","author":"Alfred Witjes","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2025.111326_b0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa2401726","article-title":"Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma","volume":"392","author":"Apolo","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2025.111326_b0015","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","article-title":"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Bellmunt","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2025.111326_b0020","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2025.111326_b0025","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2025.111326_b0030","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1200\/JCO.2004.11.024","article-title":"Surgical Factors Influence Bladder Cancer Outcomes: a Cooperative Group Report","volume":"22","author":"Herr","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111326_b0035","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ijrobp.2012.03.007","article-title":"A novel risk stratification to predict local-regional failures in urothelial carcinoma of the bladder after radical cystectomy","volume":"85","author":"Baumann","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111326_b0040","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ctrv.2018.07.011","article-title":"Risk factors for loco-regional recurrence after radical cystectomy of muscle-invasive bladder cancer: a systematic-review and framework for adjuvant radiotherapy","volume":"70","author":"Sargos","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.radonc.2025.111326_b0045","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/MOU.0b013e32833cf10e","article-title":"Follow-up of patients after curative bladder cancer treatment: guidelines vs. practice","volume":"20","author":"Vrooman","year":"2010","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.radonc.2025.111326_b0050","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0022-5347(01)66693-X","article-title":"The Relationship of Local Control to distant Metastasis in Muscle Invasive Bladder Cancer","volume":"154","author":"Pollack","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.radonc.2025.111326_b0055","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/cncr.28544","article-title":"Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710","volume":"120","author":"Christodouleas","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2025.111326_b0060","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1470-2045(14)71160-X","article-title":"Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial","volume":"16","author":"Sternberg","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2025.111326_b0065","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","article-title":"International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial","volume":"29","author":"Griffiths","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111326_b0070","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2025.111326_b0075","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/0360-3016(92)90005-3","article-title":"Postoperative radiotherapy of carcinoma in bilharzial bladder: improved disease free survival through improving local control","volume":"23","author":"Zaghloul","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111326_b0080","article-title":"Bladder Adjuvant Radiation Therapy (BART): Acute and late Toxicity from a phase III Multicenter Randomized Controlled Trial","volume":"121","author":"Murthy","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111326_b0085","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.euf.2021.11.004","article-title":"Adjuvant Radiotherapy after Radical Cystectomy for patients with High-risk Muscle-invasive Bladder Cancer: results of a Multicentric phase II Trial","volume":"8","author":"Fonteyne","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.radonc.2025.111326_b0090","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2017.4591","article-title":"Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for locally Advanced Bladder Cancer after Radical Cystectomy: a Randomized phase 2 Trial","volume":"153","author":"Zaghloul","year":"2018","journal-title":"JAMA Surg"},{"key":"10.1016\/j.radonc.2025.111326_b0095","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.ijrobp.2024.05.012","article-title":"The Value and Safety of Adjuvant Radiation Therapy after Radical Cystectomy in locally Advanced Urothelial Bladder Cancer: a Controlled Randomized Study","volume":"120","author":"Zaghloul","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111326_b0100","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ijrobp.2008.08.002","article-title":"RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer","volume":"74","author":"Lawton","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111326_b0105","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ijrobp.2016.04.032","article-title":"Development and Validation of Consensus Contouring guidelines for Adjuvant Radiation Therapy for Bladder Cancer after Radical Cystectomy","volume":"96","author":"Baumann","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111326_b0110","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ijrobp.2012.03.061","article-title":"Bladder cancer patterns of pelvic failure: implications for adjuvant radiation therapy","volume":"85","author":"Baumann","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111326_b0115","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111326_b0120","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.juro.2010.09.096","article-title":"Long-term complications of conduit urinary diversion","volume":"185","author":"Shimko","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.radonc.2025.111326_b0125","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.prro.2022.05.014","article-title":"International Consensus guidelines for Adjuvant Radiation Therapy for Bladder Cancer after Radical Cystectomy: Update from an IBIS Workgroup","volume":"12","author":"Verghote","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.111326_b0130","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.clgc.2017.05.007","article-title":"Tolerance of Orthotopic Ileal Neobladders to Radiotherapy: a Multi-institutional Retrospective Study","volume":"15","author":"Ballas","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.radonc.2025.111326_b0135","doi-asserted-by":"crossref","unstructured":"Marcq G, Souhami L, Cury FL, Salimi A, Aprikian A, Tanguay S, et al. Phase I Trial of Atezolizumab plus Trimodal Therapy in Patients with localized Muscle-Invasive Bladder Cancer. Int J Radiat Oncol Biol Phys n.d.;0. doi:10.1016\/J.IJROBP.2020.12.033.","DOI":"10.1016\/j.ijrobp.2020.12.033"},{"key":"10.1016\/j.radonc.2025.111326_b0140","doi-asserted-by":"crossref","unstructured":"Khalifa J, Sargos P. In Regard to Marcq et al. Int J Radiat Oncol Biol Phys 2021;110:916\u20137. doi:10.1016\/J.IJROBP.2021.01.058.","DOI":"10.1016\/j.ijrobp.2021.01.058"},{"key":"10.1016\/j.radonc.2025.111326_b0145","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ijrobp.2023.05.013","article-title":"Efficacy and Safety of Bladder Preservation Therapy in Combination with Atezolizumab and Radiation Therapy (BPT-ART) for Invasive Bladder Cancer: Interim Analysis from a Multicenter, Open-label, prospective phase 2 Trial","volume":"117","author":"Kimura","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111326_b0150","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.eururo.2021.09.018","article-title":"Health-related Quality of Life for patients Undergoing Radical Cystectomy: results of a Large prospective Cohort","volume":"81","author":"Clements","year":"2022","journal-title":"Eur Urol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025053307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025053307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T12:20:32Z","timestamp":1786537232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814025053307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":30,"alternative-id":["S0167814025053307"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111326","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant radiotherapy in patients with pathological high-risk bladder cancer: Acute toxicity results from a randomized multicentre phase II trial (Bladder-ART\/GETUG-AFU30)","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111326","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111326"}}